Cited by 203Cell Adhesion Molecules ResearchConnective Tissue Growth Factor ResearchBone and Dental Protein Studies

Adhesion of Human Umbilical Vein Endothelial Cells to the Immediate-Early Gene Product Cyr61 Is Mediated through Integrin αvβ3

Open access
Kireeva, Maria L., Lam, Stephen C.-T., Lau, Lester F.·1998·Journal of Biological Chemistry

Abstract

Cyr61 is a member of a family of growth factor-inducible immediate-early gene products thought to act cooperatively with the activities of growth factors. Upon synthesis, Cyr61 is secreted and is predominantly incorporated into the extracellular matrix. Recently, we demonstrated that Cyr61 promotes cell adhesion and migration and augments growth factor-induced DNA synthesis (Kireeva, M. L., Mo, F.-E., Yang, G. P., and Lau, L. F. (1996) Mol. Cell. Biol. 16, 1326-1334). In the present study, we investigated possible candidate receptor(s) on human umbilical vein endothelial cells (HUVECs) mediating adhesion to Cyr61. Under both serum-containing and serum-free conditions, adhesion of HUVECs to Cyr61 was dose-dependent, saturable, and abolished by affinity-purified anti-Cyr61 antibodies. Cell adhesion to Cyr61 was divalent cation-dependent and specifically inhibited by the peptide RGDS and LM609, a monoclonal antibody against integrin alphavbeta3. Furthermore, purified alphavbeta3 bound directly to an affinity matrix of Cyr61-coupled Sepharose 4B, and this interaction was specifically blocked by anti-Cyr61 antibodies. Additionally, in a solid phase binding assay, soluble Cyr61 bound to immobilized alphavbeta3 in a dose-dependent manner, and half-saturation binding occurred at approximately 5 nM Cyr61. As expected, the interaction of Cyr61 with immobilized alphavbeta3 was blocked by RGDS and LM609. In sum, these results identified Cyr61 as a novel ligand for alphavbeta3 and indicate that the adhesion of HUVECs to Cyr61 is mediated through interaction with this integrin. The possibility that integrin alphavbeta3 functions as a signaling receptor for Cyr61 accounts for most if not all activities that can be ascribed to Cyr61 to date and suggests a mechanism of action discussed herein.

Integrity signals

Registry

Crossref · 10.1074/jbc.273.5.3090

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • CCN1 is tightly associated with the ECM after secretion and supports cell adhesion by directly binding integrin receptors.

    “early studies on CCN1 showed that it is tightly associated with the ECM upon secretion [13] and supports cell adhesion through direct binding to integrin receptors [14,15]”

    From CCN1/CYR61: the very model of a modern matricellular protein (2011) · cites this paper as [15]

  • CCN1 promotes cell proliferation, survival, and angiogenesis by binding integrins αvβ3.

    “CCN1 promotes cell proliferation, survival and angiogenesis by binding to integrins αvβ3”

    From CCN1/CYR61: the very model of a modern matricellular protein (2011) · cites this paper as [15]

  • CCN1 was first shown to be an integrin ligand by direct binding to integrin αvβ3 to mediate endothelial cell adhesion.

    “That CCN proteins are ligand of integrins was first demonstrated by the direct binding of CCN1 to integrin αvβ3 to mediate endothelial cell adhesion [15].”

    From CCN1/CYR61: the very model of a modern matricellular protein (2011) · cites this paper as [15]

The citation lists haven’t been fetched yet

References 57 · Cited by 203

Authors
Kireeva, M. L., Lam, S. C.-T., & Lau, L. F.
Affiliations
University of Illinois Chicago (US)
Corresponding author
Lau, Lester F.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
1998-01
Volume
273
Issue
5
Pages
3090-3096
ISSN
0021-9258 (ISSN-L)
OpenAlex
W2047277690
Cited by
203
References
57
Citations by year
2025: 5 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 5 · 2020: 1 · 2019: 4 · 2018: 3 · 2017: 4 · 2016: 8 · 2015: 6 · 2014: 9 · 2013: 6 · 2012: 8
FWCI
6.37
Type
journal article
Language
en
Open access
Locations
  • Journal of Biological Chemistry (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Heart, Lung, and Blood Institute (HL41793)
  • National Cancer Institute (R01CA046565, CA-46565)
Topics
  • Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Connective Tissue Growth Factor Research
  • Health Sciences › Medicine › Rheumatology › Bone and Dental Protein Studies
Keywords
CYR61, integrin αvβ3, cell adhesion, human umbilical vein endothelial cells, RGDS peptide, integrin ligand binding, extracellular matrix, signaling receptors
MeSH terms
Antibodies, Monoclonal, Cells, Cultured, Dose-Response Relationship, Drug, Endothelium, Vascular, Fibronectins, Growth Substances, Humans, Ligands, Protein Binding, Recombinant Proteins, Umbilical Veins, Culture Media, Serum-Free, Immediate-Early Proteins, Receptors, Vitronectin, Vitronectin, Intercellular Signaling Peptides and Proteins, Cysteine-Rich Protein 61

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review